None listed
Conditions
Brief summary
One-quarter of New Zealand adults have pre-diabetes; half will develop type 2 diabetes within 7-8 years without suitable intervention. Screening for pre-diabetes currently occurs in NZ but treatment pathways are limited as stretched resources try to cope with established diabetes. The most important factor reducing the risk of progression to diabetes in those with pre-diabetes is weight loss. Although large clinical trials have demonstrated that intensive lifestyle intervention can reduce diabetes risk, simpler but still effective alternatives are also required. In this pilot, we will test the feasibility of using ‘hunger training’ as a means of facilitating weight loss in those with pre-diabetes.
Interventions
For the first 4 weeks, participants are instructed to measure their capillary or interstitial glucose (depending on whether they are randomised to Group A or B) every time they want to eat (or drink a caloric beverage). Participants are then permitted to eat only if their glucose concentration is below their individualised cut-off. Individualised glucose cut-offs are calculated as the average fasting glucose concentrations over two mornings, using the first glucose readings that are measured by fingerprick (for Group A) or scanned with the reader (from Group B). If glucose is too high, they are instructed to choose an activity that distracts them from food, and wait at least 15 minutes before testing glucose again (if hungry). Participants can consume hypocaloric drinks (e.g. black coffee or diet soft drinks) at any time. Alongside the glucose monitoring, participants indicate how hungry they were prior to measuring their glucose (1 to 10 scale), glucose concentration (if measured), and whether food was eaten (yes/no). Participants complete this hunger training ‘diary’ daily for the first month, and for one week per month thereafter (a total of 63 days). Both hunger training arms receive the same guidance and support throughout the trial, but the mechanism for measuring glucose will differ. In Group A, participants will measure their capillary glucose from a finger prick sample by portable glucometer (Abbott Freestyle Optium Glucose Meter, Australia). In Group B, participants will use the Freestyle Libre Flash Glucose Monitoring system (Abbott Diabetes Care, Australia) to measure interstitial glucose.
Sponsors
Study design
Eligibility
Inclusion criteria
Body mass index of 30kg/m2 or more, willing to measure blood glucose by fingerprick sample and continuous glucose monitor
Exclusion criteria
Pregnant, lactating, inability or unwillingness to comply with intervention requirement, taking medication that affects weight (e.g. Zyprexa, clozapine, paroxetine), known allergy to surgical adhesive, extensive skin changes/diseases on upper arm (application site of the flash sensor), has X-ray, MRI, or CT appointment scheduled during the period of study participation and cannot reschedule for a time before or after study participation.